What are the major drug interactions with Lovenox. How does Lovenox interact with other medications. What are the potential side effects of Lovenox. How should Lovenox be used safely. What precautions should be taken when using Lovenox.

Understanding Lovenox: An Overview of the Anticoagulant Medication

Lovenox, also known by its generic name enoxaparin, is a widely prescribed anticoagulant medication used to prevent and treat blood clots. As a low molecular weight heparin, Lovenox plays a crucial role in managing various cardiovascular conditions and preventing complications during surgical procedures.

This powerful medication works by inhibiting the formation of blood clots, making it an essential tool in the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism, and acute coronary syndrome. However, due to its potent effects on blood clotting, Lovenox requires careful management and consideration of potential interactions with other drugs, foods, and existing medical conditions.

Lovenox Drug Interactions: A Comprehensive Analysis

Understanding the potential interactions between Lovenox and other medications is crucial for ensuring patient safety and optimizing treatment outcomes. Based on the information provided, there are 192 known drug interactions with Lovenox, categorized as follows:

• 94 major interactions
• 92 moderate interactions
• 6 minor interactions

These interactions underscore the importance of thorough medication reviews and careful monitoring when prescribing Lovenox.

Major Drug Interactions with Lovenox

Major drug interactions pose the highest risk and should be avoided whenever possible. Some of the most frequently checked major interactions with Lovenox include:

• Warfarin (Coumadin)
• Aspirin
• Clopidogrel
• Rivaroxaban
• Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen

Why are these interactions considered major? The combination of Lovenox with these medications can significantly increase the risk of bleeding complications. For example, when Lovenox is used concurrently with warfarin or other anticoagulants, the anticoagulant effect may be potentiated, leading to an elevated risk of hemorrhage.

Moderate Drug Interactions with Lovenox

Moderate interactions, while less severe than major interactions, still require careful consideration and potential dosage adjustments. Some common moderate interactions include:

• Levothyroxine (Synthroid)
• Metformin
• Omeprazole
• Metoprolol
• Amlodipine

These interactions may necessitate closer monitoring or dosage adjustments to ensure the safe and effective use of both Lovenox and the interacting medication.

Lovenox and Alcohol/Food Interactions: What Patients Should Know

While drug interactions are a primary concern, it’s also important to consider potential alcohol and food interactions with Lovenox. The information provided indicates that there are two known alcohol/food interactions with Lovenox.

How do alcohol and certain foods interact with Lovenox? Alcohol consumption while taking Lovenox may increase the risk of bleeding, particularly in the gastrointestinal tract. Additionally, foods high in vitamin K, such as leafy green vegetables, may counteract the effects of Lovenox, potentially reducing its effectiveness.

Patients taking Lovenox should discuss their dietary habits and alcohol consumption with their healthcare provider to ensure safe and effective treatment.

Disease Interactions: Lovenox Precautions in Various Medical Conditions

The efficacy and safety of Lovenox can be significantly impacted by various medical conditions. According to the provided information, there are 12 disease interactions with Lovenox, including:

• Hemophilia
• Liver disease
• Peptic ulcer disease
• Retinopathy
• Subacute bacterial endocarditis
• Active bleeding
• Hypertension
• Renal dysfunction
• Thrombocytopenia
• Prematurity
• Kidney disease

Why are these disease interactions important? Each of these conditions can either increase the risk of bleeding complications or alter the metabolism and effectiveness of Lovenox. For instance, patients with liver or kidney disease may have impaired drug clearance, potentially leading to an accumulation of Lovenox in the body and an increased risk of bleeding.

Lovenox Dosage and Administration: Ensuring Proper Use

Proper dosing and administration of Lovenox are critical for maximizing its benefits while minimizing potential risks. The dosage of Lovenox varies depending on the specific indication, patient weight, and renal function.

How is Lovenox typically administered? Lovenox is given as a subcutaneous injection, usually in the abdominal area. The frequency of administration can range from once to twice daily, depending on the treatment regimen.

Key Considerations for Lovenox Administration

• Proper injection technique to minimize the risk of bruising or bleeding at the injection site
• Regular monitoring of platelet counts and signs of bleeding
• Adjustment of dosage in patients with renal impairment
• Careful timing of doses, especially when transitioning to or from other anticoagulants

Healthcare providers should provide thorough instructions to patients on proper self-administration techniques and signs of potential complications to watch for.

Side Effects of Lovenox: What Patients and Providers Should Monitor

While Lovenox is an effective medication for preventing and treating blood clots, it can cause various side effects. Understanding these potential adverse reactions is crucial for both patients and healthcare providers.

What are the most common side effects of Lovenox? The most frequently reported side effects include:

• Bleeding or bruising at the injection site
• Mild pain or irritation at the injection site
• Fever
• Nausea
• Diarrhea
• Swelling in the hands, feet, or ankles

More serious side effects, although less common, can include:

• Severe bleeding (including internal bleeding)
• Allergic reactions
• Thrombocytopenia (low platelet count)
• Spinal or epidural hematoma (especially following spinal procedures)

Patients should be educated on recognizing the signs of serious side effects and instructed to seek immediate medical attention if they occur.

Special Warnings and Precautions for Lovenox Use

The use of Lovenox requires careful consideration of various factors to ensure patient safety. One of the most critical warnings pertains to the risk of spinal or epidural hematoma following certain spinal procedures.

Why is this warning so important? Bleeding near the spinal cord can lead to long-lasting or permanent paralysis. Patients undergoing spinal procedures while on Lovenox should be closely monitored for signs of neurological impairment.

Additional Precautions for Lovenox Use

• Increased bleeding risk in elderly patients and those with low body weight
• Potential for adverse reactions in patients with a history of heparin-induced thrombocytopenia
• Caution in patients with artificial heart valves
• Careful use in patients with renal impairment, as drug clearance may be affected

Healthcare providers should conduct a thorough risk-benefit analysis before prescribing Lovenox, especially in patients with multiple risk factors for bleeding complications.

Lovenox in Special Populations: Pregnancy, Breastfeeding, and Pediatric Use

The use of Lovenox in special populations requires careful consideration and individualized risk-benefit assessment. Understanding its effects in pregnancy, during breastfeeding, and in pediatric patients is crucial for safe and effective use.

Lovenox and Pregnancy

Is Lovenox safe to use during pregnancy? Lovenox is generally considered safe for use during pregnancy and is often preferred over other anticoagulants due to its lower risk of crossing the placenta. However, the potential risks and benefits should be carefully weighed for each individual case.

Pregnant women taking Lovenox should be monitored closely, particularly as they approach delivery, to minimize the risk of bleeding complications during childbirth.

Lovenox and Breastfeeding

Can Lovenox be used while breastfeeding? Lovenox is considered compatible with breastfeeding, as it is not expected to be excreted in significant amounts in breast milk due to its high molecular weight. However, as with all medications, the risks and benefits should be discussed with a healthcare provider.

Pediatric Use of Lovenox

How is Lovenox used in pediatric patients? The use of Lovenox in children requires careful consideration and dosage adjustments based on weight and age. While it can be effective in treating and preventing thromboembolism in pediatric patients, close monitoring is essential due to the potential for increased bleeding risk in this population.

Pediatric dosing of Lovenox should be determined by a healthcare provider with experience in managing anticoagulation in children.

Monitoring and Management of Lovenox Therapy

Effective management of Lovenox therapy involves regular monitoring and appropriate adjustments to ensure optimal therapeutic outcomes while minimizing risks.

Key Aspects of Lovenox Monitoring

• Regular assessment of anti-Factor Xa levels, especially in high-risk patients or those on long-term therapy
• Monitoring of platelet counts to detect potential heparin-induced thrombocytopenia
• Evaluation of renal function, as Lovenox is primarily eliminated through the kidneys
• Vigilance for signs of bleeding or thrombosis

How often should patients on Lovenox be monitored? The frequency of monitoring depends on various factors, including the indication for treatment, patient risk factors, and duration of therapy. Typically, more frequent monitoring is required at the initiation of treatment and in high-risk patients.

Management Strategies for Lovenox Therapy

Effective management of Lovenox therapy may include:

• Dosage adjustments based on anti-Factor Xa levels and renal function
• Education of patients on proper self-administration techniques
• Strategies to minimize bleeding risk, such as avoiding concomitant use of certain medications
• Planning for perioperative management in patients requiring surgery

Healthcare providers should develop individualized management plans for each patient on Lovenox, taking into account their specific risk factors and treatment goals.

Alternatives to Lovenox: Exploring Other Anticoagulant Options

While Lovenox is an effective anticoagulant, there are situations where alternative medications may be more appropriate. Understanding the available options can help healthcare providers make informed decisions about anticoagulation therapy.

Common Alternatives to Lovenox

• Unfractionated heparin
• Other low molecular weight heparins (e.g., dalteparin, tinzaparin)
• Direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, or dabigatran
• Vitamin K antagonists (e.g., warfarin)
• Fondaparinux

How do these alternatives compare to Lovenox? Each anticoagulant has its own profile of benefits and risks. For example, DOACs offer the convenience of oral administration but may not be suitable for all patient populations. Unfractionated heparin can be more easily reversed in case of bleeding complications but requires more frequent monitoring.

The choice of anticoagulant should be based on factors such as the specific indication, patient characteristics, cost considerations, and potential drug interactions.

Patient Education and Counseling for Lovenox Use

Effective patient education is crucial for ensuring the safe and appropriate use of Lovenox. Healthcare providers play a vital role in counseling patients on various aspects of Lovenox therapy.

Key Points for Patient Education

• Proper technique for subcutaneous injection
• Importance of adhering to the prescribed dosing schedule
• Recognition of signs and symptoms of bleeding complications
• Awareness of potential drug and food interactions
• Importance of regular follow-up and monitoring
• Precautions to take before undergoing any medical or dental procedures

How can healthcare providers ensure effective patient education? Using a combination of verbal instructions, written materials, and demonstration of injection techniques can help reinforce important information. Encouraging patients to ask questions and express concerns can also improve understanding and adherence to treatment.

Addressing Common Patient Concerns

Patients may have various concerns about Lovenox therapy, such as:

• Fear of self-injection
• Concerns about bruising at injection sites
• Worries about potential bleeding risks
• Questions about lifestyle modifications while on therapy

Addressing these concerns proactively can help improve patient confidence and compliance with treatment.

Future Directions in Anticoagulation Therapy

As medical research continues to advance, new developments in anticoagulation therapy may impact the use of Lovenox and other anticoagulants. Staying informed about emerging trends and research can help healthcare providers optimize patient care.

Potential Areas of Future Research

• Development of novel anticoagulants with improved safety profiles
• Personalized approaches to anticoagulation based on genetic factors
• Advanced monitoring techniques for anticoagulant therapy
• Strategies for reversal of anticoagulation in emergency situations
• Long-term outcomes studies comparing different anticoagulation approaches

How might these developments impact the use of Lovenox? While Lovenox remains a valuable tool in anticoagulation therapy, future advances may lead to more tailored approaches to anticoagulation, potentially improving safety and efficacy outcomes for patients.

Healthcare providers should stay abreast of new research and guidelines to ensure they are providing the most up-to-date and evidence-based care for their patients requiring anticoagulation therapy.

Lovenox Interactions Checker – Drugs.com

Print

Save

There are 192 drugs known to interact with
Lovenox (enoxaparin), along with
12 disease interactions, and 2 alcohol/food interactions.

Of the total drug interactions,
94 are major, 92 are moderate, and 6 are minor.

Does Lovenox interact with my other drugs?

Enter other medications to view a detailed report.

• View all 192 medications that may interact with Lovenox
• View Lovenox alcohol/food interactions (2)
• View Lovenox disease interactions (12)

Most frequently checked interactions

View interaction reports for Lovenox (enoxaparin) and the medicines listed below.

• Major
• Moderate
• Minor
• Unknown

• albuterol
• amlodipine
• aspirin
• Colace (docusate)
• Coumadin (warfarin)
• Fish Oil (omega-3 polyunsaturated fatty acids)
• furosemide
• gabapentin
• hydrochlorothiazide
• Lasix (furosemide)
• levothyroxine
• Lipitor (atorvastatin)
• lisinopril
• losartan
• metformin
• metoprolol
• multivitamin
• omeprazole
• oxycodone
• potassium chloride
• prednisone
• Protonix (pantoprazole)
• simvastatin
• Synthroid (levothyroxine)
• tramadol
• Tylenol (acetaminophen)
• Vitamin C (ascorbic acid)
• Vitamin D3 (cholecalciferol)
• warfarin
• Zofran (ondansetron)

Lovenox alcohol/food interactions

There are 2 alcohol/food interactions with Lovenox (enoxaparin).

Lovenox disease interactions

There are 12 disease interactions with Lovenox (enoxaparin) which include:

• hemophilia
• liver disease
• peptic ulcer disease
• retinopathy
• subacute bacterial endocarditis
• active bleeding
• hypertension
• renal dysfunction
• thrombocytopenia
• prematurity
• hypertension
• kidney disease

Report options

Loading…

QR code containing a link to this page

More about Lovenox (enoxaparin)

• Lovenox consumer information
• Compare alternatives
• Pricing & coupons
• Reviews (20)
• Latest FDA alerts (5)
• Side effects
• Dosage information
• During pregnancy
• Generic availability
• Support group
• Drug class: heparins
• Breastfeeding
• En español

Related treatment guides

• Acute Coronary Syndrome
• Angina
• Deep Vein Thrombosis
• Deep Vein Thrombosis Prophylaxis after Abdominal Surgery

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.

Major	Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate	Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor	Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown	No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Lovenox Subcutaneous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

Warnings:

People using this medication may bleed near the spinal cord after certain spinal procedures. Bleeding in this area can cause paralysis that lasts a long time or could become permanent. Talk with your doctor about the benefits and risks before any spinal procedure. Your doctor may direct you to stop this medication for a certain amount of time before and after the procedure. Carefully follow your doctor’s directions.

The risk of bleeding may be higher if you have a deformed spine, or have had spinal procedures/surgery before (such as epidural catheter placement, difficult epidural/spinal puncture), or are taking other drugs that can cause bleeding/bruising (including antiplatelet drugs such as clopidogrel, “blood thinners” such as warfarin/rivaroxaban, nonsteroidal anti-inflammatory drugs-NSAIDs such as ibuprofen). Tell your doctor right away if you notice symptoms such as back pain, leg numbness/tingling/weakness, loss of control of the bowels or bladder (incontinence).

Warnings:

People using this medication may bleed near the spinal cord after certain spinal procedures. Bleeding in this area can cause paralysis that lasts a long time or could become permanent. Talk with your doctor about the benefits and risks before any spinal procedure. Your doctor may direct you to stop this medication for a certain amount of time before and after the procedure. Carefully follow your doctor’s directions.

The risk of bleeding may be higher if you have a deformed spine, or have had spinal procedures/surgery before (such as epidural catheter placement, difficult epidural/spinal puncture), or are taking other drugs that can cause bleeding/bruising (including antiplatelet drugs such as clopidogrel, “blood thinners” such as warfarin/rivaroxaban, nonsteroidal anti-inflammatory drugs-NSAIDs such as ibuprofen). Tell your doctor right away if you notice symptoms such as back pain, leg numbness/tingling/weakness, loss of control of the bowels or bladder (incontinence).

… Show More

Uses

Enoxaparin is used to prevent and treat harmful blood clots. This helps to reduce the risk of a stroke or heart attack. This medication helps keep your blood flowing smoothly by lowering the activity of clotting proteins in the blood. Enoxaparin is an anticoagulant, also known as a “blood thinner.” It is a type of heparin.Conditions which increase your risk of developing blood clots include certain types of surgeries (such as knee/hip replacement, abdominal), long periods of being immobile, certain types of heart attack, and a specific type of chest pain called unstable angina. For some medical conditions, enoxaparin may be used in combination with other “blood thinners.

How to use Lovenox Syringe

Read the Patient Information Leaflet if available from your pharmacist before you start using enoxaparin and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

This medication is given by injection under the skin as directed by your doctor, usually once or twice a day in the abdomen (at least 2 inches from your belly button). Do not inject into a muscle. The dosage and length of treatment are based on your medical condition and response to treatment. The dosage may also be based on your age and weight for some conditions. Use this medication regularly to get the most benefit from it. To help you remember, use it at the same time(s) each day.

If you are using this medication at home, learn all preparation and usage instructions from your health care professional and the product package. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Before injecting each dose, clean the injection site with rubbing alcohol. Change the injection site each time to lessen injury under the skin. To minimize bruising, do not rub the injection site after a shot. Learn how to store and discard medical supplies safely.

This medication may also be given by injection into a vein by a health care professional, as directed by your doctor.

Side Effects

See also Warning section.

Mild irritation, pain, bruising, redness, and swelling at the injection site may occur. Fatigue or fever may also occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

This medication can cause bleeding if its effect on your blood clotting proteins is too much. Tell your doctor right away if you have any serious signs of bleeding, including: unusual pain/swelling/discomfort, unusual or prolonged bleeding, unusual or easy bruising, dark urine, black stools, severe headache, confusion, vision changes, unusual dizziness, fainting, seizures, weakness, numbness.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US – Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

In Canada – Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Precautions

Before using enoxaparin, tell your doctor or pharmacist if you are allergic to it; or to heparin or pork products; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using enoxaparin, tell your doctor or pharmacist your medical history, especially of: artificial heart valve(s), kidney disease, liver disease, bleeding/blood problems (such as low platelet counts), low platelet counts after previous heparin treatment, stroke, high blood pressure, certain eye problems (such as diabetic retinopathy), certain stomach/intestinal problems (such as active or recent ulcers), recent spinal procedure or puncture, spine problems (such as spinal deformity), recent eye/brain/spinal cord surgery.

Limit alcohol while taking this drug because it may increase the risk of stomach bleeding.

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

To lower the chance of getting cut, bruised, or injured, use caution with sharp objects like razors and nail cutters, and avoid activities such as contact sports.

Older adults may be more sensitive to the side effects of this drug, especially bleeding.

During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.

It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

Interactions

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor’s approval.

A product that may interact with this drug is: mifepristone.

This medication is sometimes used together with other drugs that have “blood thinning” or anti-platelet effects such as aspirin, clopidogrel, or warfarin. When these combinations are prescribed by your doctor, you will require closer monitoring to minimize your risk of bleeding. Keep all medical and lab appointments.

Check all prescription and nonprescription medicine labels carefully since many medications contain pain relievers/fever reducers (NSAIDs such as ibuprofen, naproxen, or aspirin) which can increase the risk of bleeding/anti-platelet effect when used with enoxaparin. However, if your doctor has directed you to take low-dose aspirin for heart attack or stroke prevention (usually 81-162 milligrams a day), you should continue taking it unless your doctor instructs you otherwise. Ask your doctor or pharmacist for more details.

Does Lovenox Syringe interact with other drugs you are taking?

Enter your medication into the WebMD interaction checker

Overdose

If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: excessive bleeding and bruising.

Do not share this medication with others.

Lab and/or medical tests (such as complete blood count, anti-factor Xa blood levels) should be done while you are using this medication. Keep all medical and lab appointments. Consult your doctor for more details.

If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Use your next dose at the regular time. Do not double the dose to catch up.

Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.

Do not store the multiple dose vials for more than 28 days after the first use.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

Images

Lovenox 120 mg/0.8 mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 30 mg/0.3 mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 80 mg/0.8 mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 60 mg/0.6 mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 40 mg/0.4 mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 300 mg/3 mL subcutaneous solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 100 mg/mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Lovenox 150 mg/mL subcutaneous syringe

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, solution

Next

Save up to 80% on your prescriptions.

Available coupons

Save up to 80% on your prescription with WebMDRx

Drug Survey

Are you currently using Lovenox Syringe?

This survey is being conducted by the WebMD marketing sciences department.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

Today on WebMD

Lovenox Injectable – Product

Lovenox Injectable – Product – TabletWise.com

About us

• 008
• Terms of use

• Overview
• Benefits
• Side effects
• Precautions
• Interactions
• Contraindications

Overview

Lovenox Injectable / Lovenox Injectable is indicated for the treatment of deep vein thrombosis, Ischemic complications of unstable chest pain, Acute deep vein thrombosis, Non-q-wave myocardial infarction, Acute st-segment elevation myocardial infarction and other conditions .

Lovenox Injectable contains the following active ingredients: Enoxaparin Sodium. Available in injectable form.

Detailed information regarding the use, composition, dosage, side effects of Lovenox Injectable / Lovenox Injectable, as well as user reviews are provided below:

Uses

Lovenox Injectable is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:

• Deep vein thrombosis
• Ischemic complications of unstable chest pain
• Acute deep vein thrombosis 90 008
• Numbers q -wave myocardial infarction
• Acute st-segment height myocardial infarction

Learn more: Use

Side effects

The following is a list of possible side effects that may be caused by the ingredients of Lovenox Injectable. This list is not final. These side effects have been recorded previously, but are not always recorded when using the drug. Some of these side effects may be extremely rare, but have incredibly severe consequences. If you notice any side effects, contact your doctor immediately. Especially in the case of observing side effects for a long time.

• Dyspnea
• Hemorrhage
• Irritation
• Pain
• Hematoma
• Anemia
• Ecchymosis

900 06 Fever

• Nausea
• Dropsy
• Dyspnea
• Thrombocytopenia
• Confusion
• Diarrhea
• Hematuria

90 015

If If you experience side effects not listed above, contact your healthcare provider for advice. In addition, you can report side effects to your local Food and Drug Administration.

Precautions

Before starting this drug, tell your doctor about any medications you are taking, nutritional supplements (such as vitamins, natural supplements, etc. ), allergies, existing medical conditions, and current health conditions (such as pregnancy, upcoming surgery, and etc.). The side effects of the drug may be more pronounced depending on the state of your body. Take this medicine as directed by your doctor, or follow the directions for use that come with your medicine. The dosage of the drug depends on your condition. Tell your doctor if there is no change or if your condition worsens. Important points to discuss with your healthcare provider are listed below.

• monitor peak and trough anti-factor Xa levels frequently

If you use other drugs or supplements at the same time as this drug, the effects of Lovenox Injection may change. Tell your healthcare provider about all medications, vitamins, and supplements you use. Your doctor will be able to make the right plan for taking the drug, which will avoid negative interactions. Lovenox Injectable may interact with the following drugs and products:

• Acetylsalicylic acid
• Anticoagulants
• Dipyridamole
• Ketorolac tromethamine
• Salicylates
• Sulfinpyrazone

900 15

Hypersensitivity to Lovenox Injectable is a contraindication. In addition, Lovenox Injectable should not be taken if you have the following conditions:

• active severe bleeding
• hypersensitivity
  

  8

• thrombocytopenia

Composition and active ingredients

Lovenox Injectable contains the following active ingredients (salts)

• Enoxaparin Sodium

Please note that that this drug is produced with different strengths of intensity for each from the active ingredients listed above.

Packing Options and Strengths

Lovenox Injectable is available in the following pack strengths

Available packages of Lovenox Injectable / Lovenox Injectable: 100MG/ML, 300MG/3ML (100MG/ML)

FAQ

• veins and ischemic complications of unstable pain in chest?

  Yes, deep vein thrombosis and ischemic complications of unstable chest pain are among the most common reported uses for Lovenox Injection / Lovenox Injectable. Please do not use Lovenox Injectable for deep vein thrombosis and ischemic complications of unstable chest pain without consulting first with your doctor. Click here and view survey results to find out how others use Lovenox Injection / Lovenox Injectable.

• Should I use this product on an empty stomach, before or after meals?

  TabletWise.com users have reported taking Lovenox Injectable before meals. However, this information may not apply to your specific situation. Please check with your healthcare provider for a schedule. Click here and view survey results to find out what other users report as timings of using Lovenox Injectable / Lovenox Injectable.

• Is it safe to drive or operate heavy machinery while using this product?

  If you experience drowsiness, dizziness, hypotension or a headache as side-effects when using Lovenox Injection / Lovenox Injectable medicine then it may not be safe to drive a vehicle or operate heavy machinery. You should stop driving if taking this medicine makes you drowsy, dizzy, or hypotensive. Doctors recommend that you stop drinking alcohol with such drugs, because. alcohol greatly increases the side effects and drowsiness. Please check for these effects on your body when using Lovenox Injectable. Be sure to consult your doctor for advice based on the characteristics of your body and general health.

• Is this drug (product) addictive or addictive?

  Most drugs are not habit-forming or addictive. In most cases, the state classifies drugs that can be addictive as controlled dispensing drugs. For example, schedule H or X in India and schedule II-V in the USA. Please check the information on the drug packaging to make sure that this drug is not in the controlled category. Also, do not self-medicate or accustom your body to medications without consulting your doctor.

• Can I stop using this product immediately or do I need to slowly stop using it?

  Some medications need to be stopped gradually due to a rebound effect. Be sure to consult your healthcare provider for advice based on your body, general health, and other medications you may be taking.

Cite this page

Page URL

HTML Link

Lovenox Injectable

APA Style Citation

• Lovenox Injectable jetable in English – Product – TabletWise.com. (n.d.). Retrieved April 14, 2023, from https://www.tabletwise.com/us-ru/lovenox-injectable

MLA Style Citation

• “Lovenox Injectable / Lovenox Injectable in English – Product – TabletWise.com” Tabletwise.com . N.p., n.d. Web. 14 Apr. 2023.

Chicago Style Citation

• Lovenox Injectable in English – Product – TabletWise.com Tabletwise. Accessed April 14, 2023. https://www.tabletwise.com/us-ru/lovenox-injectable.

More information about Lovenox Injectable / Lovenox Injectable

• Uses of
• Reviews
• What are the uses of Lovenox Injectable / Lovenox Injectable?
• What are the side effects of Lovenox Injectable?
• What other medicines does Lovenox Injectable interact with?
• When should you not take Lovenox Injectable?
• What precautions should you take while using Lovenox Injectable?

Last updated date

This page was updated on 9/28/2020.

This page provides information for Lovenox Injectable Product in English .

Share with friends, get 20% off

Invite your friends to TabletWise learning marketplace. For each purchase they make, you get 20% off (upto $10) on your next purchase.

Use of statins, anticoagulants, antiplatelet agents and antiarrhythmic drugs in patients with COVID-19 | Shlyakhto

1. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS et al. Endothelial cell infection and endothelitis in COVID-19. The Lancet. 2020;395(10234):1417–8. DOI: 10.1016/S0140-6736(20)30937-5

2. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. Journal of Thrombosis and Haemostasis. 2020;jth.14849. [Epub ahead of print]. DOI: 10.1111/jth.14849

3. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiology. 2020; [Epub ahead of print]. DOI: 10.1001/jamacardio.2020.1286

4. Hu T, Chen B, Zhou S, Mao J. Simvastatin inhibits inflammatory response in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages through the microRNA-22/Cyr61 axis. International Journal of Clinical and Experimental Pathology. 2018;11(8):3925–33. PMID: 31949780

5. Gorabi AM, Kiaie N, Hajighasemi S, Banach M, Penson PE, Jamialahmadi T et al. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. Journal of Clinical Medicine. 2019;8(12):2051. DOI: 10.3390/jcm8122051

6. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. The Lancet Haematology. 2017;4(2):e83–93. DOI: 10.1016/S2352-3026(16)30184-3

7. Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. European Heart Journal. 2017;38(20):1608–12. DOI: 10.1093/eurheartj/ehx107

8. Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: A potential therapeutic approach to rheumatoid arthritis. Arthritis & Rheumatism. 2006;54(2):579–86. DOI: 10.1002/art.21564

9. Yuan S. Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection. mBio. 2015;6(4):e01120. DOI: 10.1128/mBio.01120-15

10. Fedson DS. Treating influenza with statins and other immunomodulatory agents. antiviral research. 2013;99(3):417–35. DOI: 10.1016/j.antiviral.2013.06.018

11. Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J et al. Association Between Use of Statins and Mortality Among Patients Hospitalized With Laboratory-Confirmed Influenza Virus Infections: A Multistate Study. Journal of Infectious Diseases. 2012;205(1):13–9. DOI: 10.1093/infdis/jir695

12. Massachusetts General Hospital. Hematology Recommendations and Dosing Guidelines during COVID-19. Version 8.0. 4/30/2020. Av. at: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/guidance-from-mass-general-hematology.pdf.

13. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. DOI: 10.1001/jama.2020.1585

14. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;e201017. [Epub ahead of print]. DOI: 10.1001/jamacardio.2020.1017

15. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A et al. Clinical Characteristics of Covid-19in New York City. New England Journal of Medicine. 2020;NEJMc2010419. [Epub ahead of print]. DOI: 10.1056/NEJMc2010419

16. European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 21 April 2020. Av. at: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance.

17. The Liverpool Drug Interaction Group. Liverpool COVID-19 Interactions. Detailed recommendations for interactions with experimental COVID-19therapies. 2020. [Internet] Available at: https://www.covid19-druginteractions.org/

18. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210

19. Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. European Heart Journal. 2020;41(19):1798–800. DOI: 10.1093/eurheartj/ehaa231

20. Kushakovsky M.S., Grishkin Yu.N. Arrhythmias of the heart. Rhythm and conduction disturbances. Causes, mechanisms, electrocardiographic and electrophysiological diagnostics, clinic, treatment: a guide for physicians. 4th ed., rev. and additional – St. Petersburg: Folio, 2014. -720s. ISBN 978-5-93929-245-0

21. Heart Rhythm Society. HRS COVID-19 Task Force Update: April 21, 2020. General guidance for QTc monitoring in COVID-19 patients. Av. at: https://www.hrsonline.org/hrs-covid-19-task-force-updateapril-21-2020.

22. Ministry of Health of the Russian Federation. Temporary guidelines. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-2019). Version 6 (04/28/2020). Available at: https://ctopcoronavirus.rf/ai/doc/194/attach/28042020_mR_COVID-19_v6.pdf

23. Shlyakhto E.V., Konradi A.O., Arutyunov G.P., Arutyunov A.G. ., Bautin A.E., Boytsov S.A. et al. Guidance for the diagnosis and treatment of diseases of the circulatory system in the context of the COVID-19 pandemic. Russian journal of cardiology. 2020;25(3):129-48. DOI: 10.15829/1560-4071-2020-3-3801

24. Arutyunov G.P., Tarlovskaya E.I., Koziolova N.A., Boldina M.V., Batyushin M.M., Ametov A. WITH. Agreed position of experts of the Eurasian Association of Physicians on the tactics of managing patients with comorbid pathology infected with SARS-Cov-2. Therapeutic archive. 2020;92(9). (in the press). DOI: 10.26442/00403660.2020.09.000703

25. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al. COVID-19and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. Journal of the American College of Cardiology. 2020;S0735109720350087. [Epub ahead of print]. DOI: 10.1016/j.jacc.2020.04.031

26. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis. 2020;jth.14810. [Epub ahead of print]. DOI: 10.1111/jth.14810

27. Arutyunov G.P., Koziolova N.A., Tarlovskaya E.I., Arutyunov A.G., Grigoryeva N.Yu., Dzhunusbekova G.A. Agreed position of experts of the Eurasian Association of Physicians on some new mechanisms of the pathogenesis of COVID19: focus on hemostasis, issues of blood transfusion and the blood gas transport system. Cardiology. 2020;60(5):1-8. DOI: 10.18087/cardio.2020.5.n1132

28. Cohen AT, Spiro TE, Spyropoulos AC, DeSanctis YH, Homering M, Büller HR et al. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. Journal of Thrombosis and Haemostasis. 2014;12(4):479-87. DOI: 10.1111/jth.12515

29. Gibson C, Spyropoulos A, Cohen A, Hull R, Goldhaber S, Yusen R et al. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open. 2017;1(1):e56–65. DOI: 10.1055/s-0037-1603929

30. Oudkerk M, Büller HR, Kuijpers D, van Es N, Oudkerk SF, McLoud TC et al. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. radiology. 2020;201629. [Epub ahead of print]. DOI: 10.1148/radiol.2020201629

31. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score: Padua Prediction Score. Journal of Thrombosis and Haemostasis. 2010;8(11):2450–7. DOI: 10.1111/j.1538-7836.2010.04044.x

32. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R et al. Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine. 2013;368(6):513–23. DOI: 10.1056/NEJMoa1111096

33. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM et al. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. New England Journal of Medicine. 2011;365(23):2167–77. DOI: 10.1056/NEJMoa1110899

34. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis. 2020;18(5):1094–9. DOI: 10.1111/jth.14817

35. Iba T, Levy JH, Warkentin TE, Thachil J, Poll T, Levi M et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis. 2019;17(11):1989–94. DOI: 10.1111/jth.14578

36. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA et al. Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):e195S-e226S. DOI: 10.1378/chest.11-2296

37. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P et l. Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility: A Randomized Trial. Annals of Internal Medicine. 2010;153(1):8. DOI: 10.7326/0003-4819-153-1-201007060-00004

38. Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.